Fig. 1
The regime of gastric cancer conversion therapy. DCS docetaxel, cisplatin, S-1; ECF epirubicin, cisplatin, 5-FU; DXP docetaxel, capecitabine, cisplatin; PCF PTX, Cisplatin, 5-FU; FOLFIRI 5-FU, leucovorin, irinotecan; FOLT 5-FU, oxaliplatin, leucovorin, docetaxel; SP S-1, cisplatin; CDDP cisplatin; EPI Epirubicin; IP irinotecan, cisplatin; TACE transcatheter arterial chemoembolization; HAIC Hepatic artery infusion chemotherapy; HIPEC hyperthermic intraperitoneal chemotherapy